Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

's hospital, an investigator at the TIMI Study group and lead author of the study.

These data represent the first clinical report of the effect of ranolazine to reduce the incidence of cardiac arrhythmias and support the findings of many prior preclinical studies which have suggested that ranolazine has potential anti-arrhythmic properties due to its action as an inhibitor of the late sodium current.

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina, and plans to submit a supplemental new drug application to the FDA in fall 2007. CV Therapeutics plans to ask the FDA to modify the existing product labeling for Ranexa by reducing cautionary language and expanding the indication to include first- line angina.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatm
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, ... has earned three Gold, three Silver, and three Bronze ... gala held in Chicago this ... the premier business awards program in the U.S. ... our company,s strength in developing leaders, cultivating talent, creating ...
(Date:7/1/2015)... ... 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker provided ... , The presentation took place on Tuesday, June 16 and provided an update on ... for the treatment of pancreatic cancer. A copy of the company overview can ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... of California, Berkeley, researchers have taken genes from grass-eating fungi ... from tough plant material cellulose that normal yeast ... the biofuels industry, which is struggling to make cellulosic ethanol ... economically feasible. "By adding these genes to yeast, ...
... available in German . , Behind every coincidence ... least. In principle, every event, including the fall of dice or ... mathematical terms. Researchers at the Max Planck Institute for the Physics ... the principle of true randomness. With the help of quantum physics, ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, announced today that Dr. Arthur ... present at the Stifel Nicolaus Healthcare Conference in Boston ... Time. A live webcast of the presentation ...
Cached Biology Technology:Researchers expand yeast's sugary diet to include plant fiber 2Researchers expand yeast's sugary diet to include plant fiber 3Researchers expand yeast's sugary diet to include plant fiber 4Random numbers game with quantum dice 2Random numbers game with quantum dice 3Random numbers game with quantum dice 4Lexicon to Present at Stifel Nicolaus Healthcare Conference 2
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... once thought to lie outside the reach of science, ... Medical Center have captured and sequenced tiny pieces of ... protein fragments—seven in all—appear to most closely match amino ... lending support to a recent and still controversial proposal ...
... study by researchers led by Kurt Kroenke, M.D., of the ... reports that nearly 20 percent of patients seen by primary ... outlines the effectiveness of a new screening tool which can ... or more anxiety disorders. The study is published in ...
... the genome sequence of the rhesus macaque monkey and ... April 13 in a special section of the journal ... share about 93 percent of their DNA, yet have ... paper, the Rhesus Macaque Genome Sequence and Analysis Consortium, ...
Cached Biology News:Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 2Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 3Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 4Anxiety disorders surprisingly common yet often untreated 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 3
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: